Kailos Genetics Enters Agreement with “Teal It’s Gone”
News Mar 31, 2016
Kailos Genetics have announced that they have entered into a partnership with Teal It’s Gone, a nonprofit organization focused on impacting ovarian and peritoneal cancer through genetic testing to provide reduced cost hereditary cancer screening.
This agreement enables Kailos and Teal It’s Gone to increase awareness of genetic testing as a tool for early cancer detection and improved treatment options by giving patients access to the Kailos hereditary cancer screening test for as low as $125. This is substantially reduced from standard hereditary cancer screening tests which are offered for upwards of $500.
“As someone who has personally been impacted by genetic testing to identify hereditary cancer, I am especially excited to partner with Kailos Genetics to provide people with affordable genetic testing,” said Katie Maxell, founder, Teal It’s Gone. “Our complementary missions to improve patient health knowledge to positively impact outcomes will enable us to make a bigger impact in people’s lives.”
According to the National Cancer Institute, genetic mutations are thought to play a role in about 5 to 10 percent of all cancers. Identifying these risks early can lead to better outcomes through earlier and more informed treatment plans.
“We want all people to have access to their health information so they can make more informed decisions. We view partnerships like this as an integral part of achieving that goal.” Brian Pollock, CEO, Kailos Genetics.
This represents Kailos Genetics’ second partnership in providing reduced cost hereditary cancer screening supported by Kailos and philanthropic funding. In October 2015, Kailos partnered with the HudsonAlpha Institute to provide free screening to women, aged 30, and reduced cost testing for all men and women in the Madison County, Alabama area.
Teal It’s Gone will launch the program regionally in certain parts of Mississippi and South Carolina, followed by national expansion.
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE